Literature DB >> 9052533

Renal failure associated with hepatitis C virus infection. Improvement in renal function after treatment with interferon-alpha.

P L Moses1, E L Krawitt, W Aziz, H L Corwin.   

Abstract

Hepatitis C virus infection can result in mixed cryoglobulinemia and associated clinical syndromes including membranoproliferative glomerulonephritis. Reports regarding the efficacy of interferon-alpha (IFN-alpha) in the treatment of patients with membranoproliferative glomerulonephritis and chronic hepatitis C infection have been inconclusive regarding improvement of renal function. We describe two patients with chronic hepatitis secondary to hepatitis C virus complicated by mixed cryoglobulinemia and membranoproliferative glomerulonephritis who developed severe renal failure which resolved after treatment with standard doses of IFN-alpha 2b.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9052533     DOI： 10.1023/a:1018803027109

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  14 in total

1.  Hepatitis C--associated glomerular disease in liver transplant recipients.

Authors:  C L Davis; D R Gretch; J D Perkins; A W Harris; M H Wener; C E Alpers; R Lesniewski; W Lee; C dela Rosa; R J Johnson
Journal:  Liver Transpl Surg       Date:  1995-05

Review 2.  Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease.

Authors:  M Houghton; A Weiner; J Han; G Kuo; Q L Choo
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

Review 3.  Renal manifestations of hepatitis C virus infection.

Authors:  R J Johnson; R Willson; H Yamabe; W Couser; C E Alpers; M H Wener; C Davis; D R Gretch
Journal:  Kidney Int       Date:  1994-11       Impact factor: 10.612

4.  Hepatitis-B-associated glomerulonephritis: pathology, pathogenesis, and clinical course.

Authors:  V S Venkataseshan; K Lieberman; D U Kim; S N Thung; S Dikman; V D'Agati; M Susin; E Valderrama; B Gauthier; A Prakash
Journal:  Medicine (Baltimore)       Date:  1990-07       Impact factor: 1.889

5.  Hepatitis C virus infection in patients with essential mixed cryoglobulinemia.

Authors:  R Misiani; P Bellavita; D Fenili; G Borelli; D Marchesi; M Massazza; G Vendramin; B Comotti; E Tanzi; G Scudeller
Journal:  Ann Intern Med       Date:  1992-10-01       Impact factor: 25.391

6.  Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa.

Authors:  H S Conjeevaram; J H Hoofnagle; H A Austin; Y Park; M W Fried; A M Di Bisceglie
Journal:  Gastroenterology       Date:  1995-08       Impact factor: 22.682

7.  Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes.

Authors:  J M Pawlotsky; F Roudot-Thoraval; P Simmonds; J Mellor; M B Ben Yahia; C André; M C Voisin; L Intrator; E S Zafrani; J Duval; D Dhumeaux
Journal:  Ann Intern Med       Date:  1995-02-01       Impact factor: 25.391

8.  Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon.

Authors:  C Y Lin
Journal:  Kidney Int       Date:  1995-01       Impact factor: 10.612

Review 9.  Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients.

Authors:  P D Gorevic; H J Kassab; Y Levo; R Kohn; M Meltzer; P Prose; E C Franklin
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

10.  A lethal course of chronic hepatitis C, glomerulonephritis, and pulmonary vasculitis unresponsive to interferon treatment.

Authors:  F X Roithinger; S Allinger; A Kirchgatterer; F Prischl; R Balon; A Haidenthaler; P Knoflach
Journal:  Am J Gastroenterol       Date:  1995-06       Impact factor: 10.864
View more
  1 in total

1.  Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients.

Authors:  Soledad Retamozo; Cándido Díaz-Lagares; Xavier Bosch; Albert Bové; Pilar Brito-Zerón; Maria-Eugenia Gómez; Jordi Yagüe; Xavier Forns; Maria C Cid; Manuel Ramos-Casals
Journal:  Medicine (Baltimore)       Date:  2013-09       Impact factor: 1.889
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.